Plain-English translation of NCT06392295 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating prostate cancer that has come back in the lymph nodes after earlier treatment. The study combines radiation therapy directed at specific areas where cancer has returned with hormone-suppressing medication. Researchers want to see if this combination approach can control the cancer better while keeping your quality of life as good as possible.
Many men with prostate cancer see their cancer return in nearby lymph nodes after initial treatment, but it's not clear what the best way to treat this limited recurrence is. This trial explores whether adding targeted radiation to these specific areas—guided by special imaging—can improve cancer control when used alongside hormone therapy.
You likely qualify if…
You likely don't qualify if…
You will receive up to six months of hormone-blocking medication combined with five weeks of specialized radiation therapy targeting the areas where your cancer has returned. The radiation is guided by special imaging that shows exactly where the cancer is located. You will be followed for up to five years total, with regular check-ups to monitor how well the treatment works and how you are feeling. You will also be asked to complete questionnaires about your quality of life and overall well-being throughout the study.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States